Search
EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA
CMO Gianfranco Pittari walks us through data from the pivotal ARES study that MaaT announced in January and filed with the EMA. Plus, an...
Jun 14
Microsoft's Chief Scientific Officer for Health and Life Sciences shares his take on how AI is changing healthcare today and what is possible in the future
Matthew Lungren describes his belief how AI will "save time before it saves lives," and discusses how the clinical workforce is getting...
Jun 13
EHA 2025: CEO Arthur Sands discusses Nurix Therapeutics' BTK degrader data, the development plan ahead, recent #AACR25 data regarding brain penetration, and activity in the autoimmune space
He discusses the P1 data presented at EHA for CLL and WM, which he says showed efficacy across mutations, durability, and clean safety....
Jun 13
EHA 2025: CEO Jonathan Dickinson discusses Innate Pharma's NK cell engager platform (ANKET), recent ASCO data for Lacutamab, and other program updates
He describes Innate's NK cell platform and covers programs targeting CD20, CD123, BCMA, and B7-H3. Plus Lacutamab data, updates on the...
Jun 13
CLAIRITY BREAST, an AI platform that predicts five-year breast cancer risk from routine mammograms, became the first such AI tool to receive FDA authorization for breast cancer prediction
CEO Leff Luber describes the tool, which is mean to augment a radiologist's analysis, and how its modeling algorithm takes into account...
Jun 11
Cullinan Therapeutics' CEO Nadim Ahmed covers last week's #ASCO25 data for zipalertinib in EGFRex20 insertion lung cancer, plus an in-depth conversation about bispecifics for autoimmune conditions
He highlights the zipalertinib ASCO data, which was in the relapsed setting and will be used by Cullinan's partner, Taiho, to file for...
Jun 10
Nucleate UK held its "The Forum" event in London - where it brought together the biotech community for networking, education, and to celebrate companies that have been through its Activator program
BiotechTV attended the event, and recorded comments from the Nucleate team, who describe the scale and role of Nucleate in this area. We...
Jun 9
AI News: Artera presented data at #ASCO25 showing that its AI platform can identify prostate cancer patients most likely to benefit (or not benefit) from added androgen receptor inhibitor therapy
CMO Tim Showalter describes the finding, which was selected as a "Best of ASCO" oral presentation. Plus, helping to determine how certain...
Jun 6
Kymera Therapeutics' Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data
He describes the data, which was released on Monday, and highlights the future of the program - including how we will see more data in...
Jun 4
ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer
Global Product Lead José Antonio López-Vilariño describes the data and VP of Strategic Development Pascal Besman puts the result in...
Jun 3
Klein Hersh at #ASCO25
Lonnie Brantz, Zach Spitz, and Jeffrey Azarva stopped by to discuss oncology trends, the evolving talent landscape, and the importance of...
Jun 2
ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer
Chairman and CEO Alessandro Riva describes the computational work that is done to choose the personalized neoantigens for this cancer...
Jun 2
ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy
He explains the design of the therapy, and covers the data presented at ASCO. Plus, filing and manufacturing plans, and highlighting this...
Jun 2
ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy
He explains why IL-12, and how the self-replicating aspect may be giving this more durability over first generation mRNA cancer...
Jun 2
ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate
CEO David Chang describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on...
Jun 2
ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging
Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new...
Jun 2
BioVenture VoiCes Episode 20: Breakout Ventures' Lindy Fishburne
Lindy Fishburne describes her educational background and career, and transitioning from the philanthropic Breakout Labs within the Thiel...
Jun 2
Deerfield Management Managing Partner James Flynn discusses a new $600M venture fund the firm has raised and describes how it will be invested, including into AI companies
He describes raising the fund, and his take on the current challenging environment in healthcare. Plus, his thoughts on AI specifically,...
Jun 2
ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R
He describes the Rusfertide result, which is partnered with Takeda and was presented in a plenary session at ASCO. Plus, he covers a UC...
Jun 1
ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor
She describes Bicara's data in HPV-negative HNSCC, and explains why the company is focused on this HVP-negative population specifically....
Jun 1
.png){kind=logo}
